瑞银发表报告,列出最具潜力超市场预期收益((Buy rated HK listed stocks with highest UBSe earnings upside above consensus estimate)的港股买入名单:股份│瑞银与同业对企业今明两年综合盈测差异康希诺生物(06185.HK) +2.060 (+4.376%) 沽空 $1.04千万; 比率 10.171% │97%石药集团(01093.HK) +0.680 (+6.773%) 沽空 $4.36亿; 比率 24.736% │60%三生制药(01530.HK) +0.580 (+1.902%) 沽空 $1.51亿; 比率 9.857% │42%科济药业-B(02171.HK) +0.560 (+2.732%) 沽空 $4.40百万; 比率 18.763% │42%上石化(00338.HK) 0.000 (0.000%) 沽空 $84.79万; 比率 7.910% │37%越秀地产(00123.HK) -0.010 (-0.206%) 沽空 $1.53百万; 比率 2.458% │35%金风科技(02208.HK) -0.020 (-0.234%) 沽空 $1.48千万; 比率 15.274% │33%科伦博泰生物-B(06990.HK) +14.800 (+3.667%) 沽空 $2.22千万; 比率 6.767% │27%中信建投证券(06066.HK) +0.450 (+3.396%) 沽空 $3.52千万; 比率 10.167% │26%恒瑞医药(01276.HK) +3.450 (+4.579%) 沽空 $5.72千万; 比率 13.895% │25%海丰国际(01308.HK) +0.220 (+0.815%) 沽空 $1.37千万; 比率 13.973% │23%药明康德(02359.HK) +6.200 (+6.194%) 沽空 $1.43亿; 比率 9.565% │22%(wl/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-08-13 16:25。)